WO1996016650A1 - Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive - Google Patents
Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive Download PDFInfo
- Publication number
- WO1996016650A1 WO1996016650A1 PCT/JP1995/002347 JP9502347W WO9616650A1 WO 1996016650 A1 WO1996016650 A1 WO 1996016650A1 JP 9502347 W JP9502347 W JP 9502347W WO 9616650 A1 WO9616650 A1 WO 9616650A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- hydrogen atom
- lower alkyl
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- Antibacterial or bactericide comprising 2-aminothiazole derivative and its salts
- the present invention relates to an antibacterial agent or a bactericide comprising a 2-aminothiazole derivative and salts thereof.
- the bactericide according to the present invention includes a disinfectant / bactericide.
- the present invention relates to an antibacterial agent or a bactericide having a low tendency to have resistance and a low toxicity comprising a 2-aminothiazole derivative or a salt thereof, and having an antibacterial activity or a bactericidal activity, and a drug containing the antibacterial agent or the bactericide. It is intended to provide
- the present invention relates to a novel antibacterial or bactericide containing a 2-aminothiazole derivative and salts thereof as an active ingredient.
- R 'and R 2 are a hydrogen atom, a halogen atom, a lower alkyl group, a lower cycloalkyl group, a substituted or unsubstituted phenyl group, a thiophene group, a benzoyl group, a benzoylmethyl group, a benzyl group or a substituted benzyl group.
- a 2 represents a hydrogen atom, a lower alkanesulfonyl group, a halo-lower alkanesulfonyl group, a phenyl group or a substituted phenyl group, a substituted benzyl group, a substituted benzyl group, substituted or unsubstituted A benzenesulfonyl group, a substituted or unsubstituted lower alkanol group, an amidino group, —CO—R 5 ⁇ wherein R 5 is a lower alkyl group, Weniru or substituted Fuweniru group one (CH 2) m - CO OH (wherein, m is an amidino group, —CO—R 5 ⁇ wherein R 5 is a lower alkyl group, Weniru or substituted Fuweniru group one (CH 2) m - CO OH (wherein, m is an
- the general formula (I) will be specifically described.
- the halogen atom include fluorine, chlorine, bromine and iodine.
- the lower alkyl groups include methyl, E Chinore, n- Puropinore, iso- propyl, n- butyl, iso- butyl, carbon atoms, such as tert- butyl C, and alkyl group -C e are exemplified.
- Examples of the lower cycloalkyl group include a cycloalkyl group having 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentane, and cyclohexane.
- Lower alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyl 6/16650
- Examples thereof include C 3 -C 6 alkoxy groups such as 1-3-toxyl, iso-butoxy, tert-butoxy and the like.
- the lower alkanesulfonyl group includes C 4 to C 4 such as methanesulfonyl, ethanesulfonyl, n-propanesulfonyl, iso-propanesulfonyl, n-butanesulfonyl, iso-butanesulfonyl, tert.-butanesulfonyl and the like.
- An alkanesulfonyl group is exemplified.
- one t is a lower-alkanesulfonyl group substituted with a plurality of halogen atoms, for example, a fluoromethanesulfonyl group, a chloromethanesulfonyl group consisting of mono, di, and tri, Examples thereof include a bromomethanesulfonyl group, a fluorescein ethanesulfonyl group, a chloromouth ethanesulfonyl group, and a bromoethanesulfonyl group.
- the substituted or unsubstituted lower Arukanoiru groups was amino group or a 1-3 carbon atoms substituted with a halogen atom C, a halo-lower Arukanoi Le group -C 4, for example, aminoacetyl group, Monofuru Chloroacetyl group, difluoroacetyl group, trifluoroacetyl group, monochloroacetyl group, dichloroacetyl group, trichloroacetyl group, monofluoropropionyl group, difluoropropionyl group, trifluorochloropropionyl group and the like. You.
- Examples of the lower alkanoyloxy group include alkanoyloxy groups having a carbon number of C 1 to C 6 , such as acetyl, propionyl, butyryl, valeryl, and vivaloyl.
- Examples of the cyclic amino group include a 5- or 6-membered cyclic amino group which may contain a nitrogen atom or an oxygen atom such as piperidino, pyrrolidino, morpholino, piperazino, and pipecolino (in addition to a halogen atom and a lower alkyl group. Which may be substituted).
- Substituents of substituted phenyl, substituted benzyl, substituted pyridyl and substituted benzenesulfonyl include lower alkyl, halogen, hydroxyl, nitro, phenyl, trifluoromethyl, lower alkoxy, one or more Halo-lower alkoxy, lower alkanesulfonyl, halo-lower alkanesulfonyl, amino, dimethylamino, getylamino, di-n-propylamino, di-n-butylamino, etc.
- di-lower alkylamino group methylsulfonyl, ethylsulfonyl, n-propylsulfinyl, iso-propylsulfonyl, n-butylsulfonyl, tert.-butylsulfonyl, etc.
- the pharmaceutically acceptable salts thereof include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, and maleic acid, fumaric acid, oxalic acid, succinic acid, malonic acid, lactic acid, citric acid, methanesulfonic acid, and benzenesulfone.
- Organic acids such as acid and acetic acid; or alkali metal salts such as lithium salt, sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; inorganic salts such as ammonium salt;
- Organic salts such as, but not limited to, mine salts, ethanolamine salts, triethanolamine salts, and dicyclohexylamine salts.
- the compound represented by the general formula (I) or a salt thereof is used as a medicine, it is used in the form of a general pharmaceutical preparation such as an injection, a topical external preparation, and an oral preparation.
- a general pharmaceutical preparation such as an injection, a topical external preparation, and an oral preparation.
- Formulations are prepared using commonly used fillers, extenders, binders, moisturizers, disintegrants, surfactants, diluents such as lubricants, and diluents.
- Typical examples are tablets, pills, suppositories, injections, pastes, plasters, creams, gels, gel-like creams, lotions, compresses, plasters, liniments, and liquids. , Aerosols, powders, granules, capsules, syrups, oral preparations, eye drops, nasal drops, etc., usually in a stable form, usually systemically or locally, orally or parenterally. can do.
- a wide variety of carriers conventionally known in the art can be used as a carrier, such as lactose, sucrose, sodium chloride, glucose, urea, starch, and carbon dioxide.
- Excipients such as lucidum, kaolin, microcrystalline cellulose, gay acid, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, etc.
- Binders dry starch, sodium alginate, powdered agar, powdered laminarane, powdered sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglyceride stearate, starch, lactose, disintegrants, sucrose , Stearin, cocoa butter, hydrogenated oils, etc., disintegration inhibitors, quaternary ammonium bases, absorption promoters such as sodium lauryl sulfate, humectants such as glycerin, starch, starch, lactose, kaolin Pentona I DOO, adsorbent such as colloidal Gay acid, purified talc, stearates, boric acid powder, lubricant and the like such as polyethylene glycol can be exemplified.
- tablets can be made into tablets coated with a usual coating, if necessary, such as sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets or double tablets or multilayer tablets.
- a wide variety of carriers conventionally known in this field can be used as a carrier, for example, excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, kaolin, talc, and gum arabic powder.
- binders such as tragacanth powder, gelatin and ethanol, and disintegrants such as laminaran agar.
- the suppository base is appropriately selected from conventionally known suppository bases, that is, lipophilic bases, water-soluble bases, and emulsion bases.
- the suppository base is selected from, for example, synthetic oil bases such as cocoa butter, hydrogenated laccase oil and hydrogenated coconut oil, and water-soluble bases such as polyethylene glycols, monolen, propylene, and pluronic.
- An antimicrobial or bactericide which is a medicinal ingredient, is added to the base in an amount of 0.01 to 10% by weight, an ultraviolet absorber is added in an amount of 0.01 to 5% by weight, and if necessary, an antioxidant is added in an amount of 0.01 to 5% by weight.
- the suppository formulation containing the antibacterial agent or the bactericide of the present invention can be obtained.
- additives that can be added as needed include local anesthetics, antihistamines, local astringents, sulfa drugs, antibiotics, anti-acne treatments, surfactants, vitamins, herbal extracts, bile acids, preservatives, and preservatives. Excipients, absorption enhancers, amino acids and the like are used.
- liquids, emulsions, and opacifiers are preferably sterilized and isotonic with blood.Dilution when forming these liquids, emulsions, and opacifiers
- the agent those conventionally known in this field can be widely used, and examples thereof include water, an aqueous solution of lactate, ethyl alcohol, propylene glycol, and polyoxyethylene sorbitan fatty acid esters.
- the pharmaceutical preparation may contain a sufficient amount of salt, glucose or glycerin to prepare an isotonic solution, and may also contain ordinary solubilizing agents, buffers, soothing agents, etc. May be added. Further, if necessary, coloring agents, preservatives, flavors, flavoring agents, sweeteners, and other pharmaceuticals may be contained in the pharmaceutical preparation.
- the ointment base may be selected from known or commonly used ones.
- higher fatty acids or their esters eg, adipic acid, myristic acid, panolemitic acid, stearic acid, oleic acid, adipine
- the gel base is selected from various known or commonly used bases. Examples thereof include lower alcohols (eg, ethanol, isopropyl alcohol, etc.), water, and gelling agents (eg, carboxyvinyl polymer, hydroxyethyl resenorelose, Droxypropyl senorellose, methinoresenorelose, ethylsenorellose, carboxymethylcellulose, propylene glycol alginate, etc.), neutralizing agent (eg, triethanolamine, diisopropanolamine, sodium hydroxide, etc.), surfactant Agents (Examples: sorbitan sesquioleate, sorbitan trioleate, sorbitan monooleate, sorbitan monostearate, sorbitan monolaurate, polyethylene glycol monostearate, polyoxyethylene Nonylphenyl ether, polyoxyethylene cetyl ether, polyoxyethylene lauryl ether, etc.), absorption
- lower alcohols eg
- Cream bases are known or commonly used For example, higher fatty acid esters (eg, myristate, palmitate, getyl sebacate, hexyl laurate, cetyl isooctanoate), lower alcohols (eg, ethanol, isopropanol) ), Carbohydrates (eg, liquid paraffin, squalane, etc.), polyhydric alcohols (eg, propylene glycol, 1,3-butylene glycol, etc.), higher alcohols (eg, 2-hexyldecanol, cetanol, 2- Octyldodecanol, etc.), emulsifiers (eg, polyoxyethylene alkyl ethers, fatty acid esters, polyethylene glycol fatty acid esters, etc.), preservatives (eg, paraoxybenzoic acid ester), absorption promoters (eg, propylene carbonate, Jechir Sebagate, Ji Sop Ropir adipate,
- a gelling agent eg, carboxyvinyl polymer, hydroxyethyl cellulose, hydroquin propyl cellulose, And a neutralizing agent (eg, diisopropanolamine, triethanolamine, sodium hydroxide, etc.)
- the pH value is 4 to 8, preferably 5 to 6.5.
- a gelling agent is added to (B) water to cause swelling, and then (B) is added to (A) and uniformly emulsified by a homomixer. When added, and the pH value is adjusted to 4 to 8, the gel cream of the present invention is obtained.
- Compress base for example, thickener (eg, sodium polyacrylate, polyacrylic acid, poval, polyvinylpyrrolidone, polyethylene oxide Synthetic water-soluble polymers such as side and polyvinyl methacrylate, natural products such as gum arabic, starch and gelatin, methylcellulose, hydroxypropylcellulose, alginic acid, sodium alginate, ammonium alginate, sodium carboxymethylcellulose, etc.
- thickener eg, sodium polyacrylate, polyacrylic acid, poval, polyvinylpyrrolidone, polyethylene oxide Synthetic water-soluble polymers such as side and polyvinyl methacrylate, natural products such as gum arabic, starch and gelatin, methylcellulose, hydroxypropylcellulose, alginic acid, sodium alginate, ammonium alginate, sodium carboxymethylcellulose, etc.
- Humectant eg, urea, glycerin, propylene glycol, butylene glycol, sorbitol, etc.
- filler eg, kaolin, zinc oxide, talc, titanium, benite, epoxy resins, organic acids (citric acid, tartaric acid, Maleic acid, maleic anhydride, succinic acid, etc.), calcium, magnesium, aluminum, etc.), water, solubilizers (eg, propylene carbonate, crotamiton, diisopropyl adipate, etc.), tackifiers (eg, rosin, Stellumum, polybutene, polyacrylic acid ester, etc.), anti-rash agents (eg, diphenylhydramine hydrochloride, chlorpheniramine maleate, glycyrrhizic acid, dexamethasone, betamethasone, fluocinolone acetonide), and others
- additives eg, salicylic acid
- (A) is added to (B) and mixed to obtain a uniform kneaded product.
- the kneaded product of the present invention can be obtained by spreading and applying this kneaded product on a support by a usual method, and then applying a release coating thereon.
- the support is selected from stretchable or non-stretchable fabric, nonwoven fabric, non-woven paper, etc.
- the release coating is selected from polyethylene, polypropylene, polyvinyl chloride, polyester, polyvinylidene chloride, siliconized paper, etc. Is done.
- Bases for plasters are known polymer bases (eg, acrylic compositions which are copolymers with vinyl monomers such as methacrylates, acrylonitrile, vinyl acetate, vinyl propionate, silicone resins) , Poly Soprene rubber, polyisobutylene rubber, natural rubber, acrylic rubber, styrene butagen-styrene block copolymer, styrene-isoprene-styrene block copolymer, etc., fats and oils or higher fatty acids (eg, almond oil, olive oil, Selected from camellia oil, basic oil, laccase oil, oleic oil, liquid paraffin, polybutene, etc.), tackifier (eg, rosin, rosin-modified maleic acid, hydrogenated rosin ester, etc.), anti-rash agent
- Other additives to the base eg d 1-camphor, 1-menthol, thymol, penilyl nonylate, capsi
- This is a stretchable or non-stretchable support eg, polypropylene, polyester, polyvinylidene chloride, polyacrylic, polyurethane, rayon, cotton, ethylene-vinyl acetate copolymer, cloth, nonwoven fabric, nonwoven paper, etc.
- the production of plasters can be easily carried out in accordance with a generally known method.
- the composition of the plasters is determined by replacing the medicinal component in a known cool or warm plaster with an antibacterial agent or a bactericide. To 10% by weight, and further adding 0.01 to 5% by weight of an ultraviolet absorber or 0.01 to 5% by weight of an antioxidant as needed to obtain the plaster of the present invention. it can.
- the liniment of the present invention may contain alcohols (eg, monohydric alcohols such as ethanol, propanol and isopropanol, polyhydric alcohols such as polyethylene glycol, propylene glycol and butylene glycol, etc.) 10 to 70% by weight, water 5 5% by weight or less, fatty acid ester (eg, various esters of adipic acid, sebacic acid, myristic acid, etc.) 60% by weight or less, surfactant (eg, polyoxyethylene alkyl ether) 10% by weight or less Add 0.1 to 10% by weight of antibacterial agent or bactericide, which is a component, and add 0.01 to 5% by weight of ultraviolet absorber and 0.01 to 5% by weight of antioxidant if necessary.
- alcohols eg, monohydric alcohols such as ethanol, propanol and isopropanol, polyhydric alcohols such as polyethylene glycol, propylene glycol and butylene glycol, etc.
- fatty acid ester eg
- the above formulation examples and production examples are merely examples, and the liniment of the present invention can be naturally obtained by a known method for producing liniment. Also, in the composition Also in this case, the liniment of the present invention can be easily obtained by replacing the active ingredient of the known liniment with an antibacterial agent or a bactericide and blending it with an ultraviolet absorber.
- a neutralizing agent for adjusting pH a viscosity-imparting agent such as methylcellulose, carboxyvinyl polymer, or hydroxypropylcellulose, a rash preventive, or other additives (eg, Salicy) Lactic acid, methyl salicylate, glycol salicylate, menthol, camphor, heart oil, pepper extract, penylyl nonylate, thymol, crotamiton, aison, propylene carbonate, diisopropyl adipate, pyrothiodecane, etc.) .
- Salicy Lactic acid, methyl salicylate, glycol salicylate, menthol, camphor, heart oil, pepper extract, penylyl nonylate, thymol, crotamiton, aison, propylene carbonate, diisopropyl adipate, pyrothiodecane, etc.
- liquids are used as disinfectants.
- the amount of the antibacterial or bactericide to be added to the solution should be 0.01 to 10% by weight.
- a primary, secondary or tertiary monoalcohol having 1 to 4 carbon atoms is preferable.
- ethanol, ethanol for disinfection, anhydrous ethanol, isopropanol, propanol, butanol and the like can be mentioned.
- the amount of these lower monoalcohols is preferably 60 to 90% by weight based on the whole liquid preparation. If the amount of the lower monoalcohol is less than 60% by weight, a sufficient antibacterial or bactericidal effect cannot be obtained, and if it is more than 90% by weight, the retention time of foam may be short and impractical.
- nonionic surfactant to be incorporated in the liquid preparation of the present invention examples include polyoxyethylene sorbitan acyl ester polysorbate 80, polysorbate 60, polysorbate 20 and silicone polyether copolymer dimethylsiloxane (POE) Siloxane copolymer, etc .: polyoxyethylene acyl ester polyoxyl 40, polyoxyethylene lauryl ether, etc .; polyoxyethylene alcohol ether lauromacrogam, etc .; stearic acid glycerin ester Glycerin monostearate and decaglycerin monolaurate, etc .; sorbitan fatty acid ester span 60 monostearate, etc .: sorbitan acyl ester sorbitan sesquioleate, etc .; polyoxyhydrogenated castor oil HCO-6 0, HCO-50, etc .; polyoxyethylene propylene Pull-mouth nick F68 of lenglycol monofatty acid ester and the like can be mentioned.
- the HLB of these nonionic surfactants is preferably 10 or more. If the HLB is less than 10, it may be difficult to obtain a desired foam having appropriate stability.
- the amount of the activator is preferably 0.5 to 3% by weight, more preferably 1 to 3% by weight, based on the whole liquid preparation. If the amount is less or more than this, it may be difficult to obtain a foam having appropriate stability as described above.
- the water-soluble polymer compound a natural or synthetic polymer compound is used.
- the natural polymer compound include soluble polysaccharides such as acacha gum, xanthan gum, pectin, carrageenan, sodium alginate, etc., soluble polypeptides such as gelatin, chitins such as chitin and chitosan.
- the synthetic polymer compound include a partially polymerized natural polymer compound, for example, sodium carboxymethyl cellulose and hydroxypropyl cellulose, which are soluble polysaccharides.
- the child compound examples include polyvinyl alcohol-based compounds such as polyvinyl alcohol and derivatives thereof, and polyvinyl pyrrolidone-based compounds such as polyvinyl pyrrolidone and derivatives thereof.
- xanthone gum is preferred from the viewpoint of foam stability. It is preferable that the blending amount is 0.01 to 3% by weight based on the whole liquid preparation. If the amount is out of this range, it may be difficult to obtain a foam having appropriate stability as described above.
- humectant incorporated in the liquid preparation of the present invention examples include glycerin, propylene glycol, sorbitol, 1,3-butylene glycol, macrogol 400, hyaluronic acid and the like. Particularly, foam stability, defoaming Glycerin is preferred from the viewpoints of properties and moisturizing properties.
- foam stability, defoaming Glycerin is preferred from the viewpoints of properties and moisturizing properties.
- One or more of these humectants may be blended in any ratio.
- from glycerin to macrogol 400 1 to 10% by weight of the whole liquid
- hyaluronic acid is the whole liquid It is preferable to add 0.01 to 1% by weight based on the weight.
- water may be blended in the liquid preparation of the present invention, and in this case, the blending amount is the whole liquid preparation. 3 to 35% by weight.
- Water acts on a surfactant to improve foaming, and acts on a water-soluble polymer compound to stabilize foam.
- the retention time of foam can be appropriately adjusted by combining a high concentration of lower monoalcohol with a predetermined nonionic surfactant. Normally, when about 0.5 to 2 g of foam liquid is applied to the palm and the hands are rubbed, the range that the user perceives if the liquid spreads sufficiently and the foam remains too long will be experienced. Typically 5 to 30 seconds. To prepare an easy-to-handle and effective solution, it is necessary to use a high concentration of alcohol and keep the form retention time within this range. Further, the liquid preparation of the present invention can maintain a clear and stable state of the form by appropriately mixing a water-soluble polymer compound.
- the liquid preparation of the present invention is usually made into an aerosol composition together with a propellant.
- the propellant include dimethyl ether, liquefied petroleum gas, N 2 gas, nitrous oxide gas, CO 2 gas, and CFC alternative gas which are usually used for aerosol. Compressed air can be used without using a propellant. Moreover, you may use these mixtures.
- the amount of the propellant is not particularly limited, but is preferably 0.1 to 80% by weight based on the total amount of the liquid preparation of the present invention.
- an appropriate amount of a perfume or a component usually blended in an external preparation for example, 1-menthol, tocoprol acetate, or a vegetable oil or animal oil such as castor oil or squalene may be used in an appropriate amount.
- the dose of the antibacterial agent or the bactericide of the present invention is appropriately determined depending on the condition, age, sex, etc. of the administration subject. Usually, when orally administered to an adult, the compound (I) has a certain t, It is preferable to administer the salt at a dose of about 10 to 500 mg 1 about 1 to several times.
- the compound represented by the general formula (I) is produced, for example, by the method described in the above-mentioned Japanese Patent Application Laid-Open No. 3-173876 or a method analogous thereto.
- Manufacturing method 1 For example, the production method shown in the following reaction formula. Manufacturing method 1
- the compound represented by the general formula ( ⁇ ) and the compound represented by the general formula (III) or (IV) are cooled in a suitable solvent in the presence of a base catalyst or at room temperature. Is reacted for about 0.5 to 30 hours under heating to obtain the compound represented by the general formula (I) or
- the compound represented by (1 ′) can be obtained.
- the reaction solvent used herein is, for example, an organic solvent that does not participate in the reaction, such as dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, N, N-dimethylformamide, N, N-dimethylacetamide, and dimethylsulfoxide. If it is, there is no particular limitation.
- the base catalyst include, but are not limited to, pyridine, collidine, triethylamine, tri-n-butylamine, and other basic catalysts that promote the deoxidation reaction.
- the production method 2 comprises a compound represented by the general formula (V) and a compound represented by the general formula (VI).
- the compound represented by the general formula (I) can be obtained by mixing the compound in an appropriate solvent at room temperature or under heating.
- the reaction solvent include, but are not limited to, methanol, ethanol, tetrahydrofuran, N, N-dimethylformamide, dimethylsulfoxide and the like.
- FIG. 1 is a graph showing the relationship between the minimum inhibitory concentration of Staphylococcus aureus and the number of passages.
- FIG. 2 is a graph showing the relationship between the minimum inhibitory concentration of Staphylococcus epidermidis and the number of passages.
- the book shows compound No. 9 line 1, ⁇ shows compound No. 9 line 2, ⁇ shows GM line 1, and ⁇ shows GM line 2.
- the compound represented by the general formula (I) can be administered as it is or together with a conventional pharmaceutical carrier.
- the dosage unit form is not particularly limited, and may be appropriately selected and used as needed.
- This formulation example is merely an example, and various formulations can be made according to a known method.
- a cream is prepared according to the following formulation (100 parts by weight in total).
- Compound 2 represented by the general formula (I) is represented by the general formula (I)
- An ointment is prepared according to the following formulation (100 parts by weight in total).
- a lotion is prepared according to the following formulation (total amount: 100 parts by weight) —Compound represented by general formula (I) 2 Diisopropyl adipate 5 Macrogol 400 10 Oleyl alcohol 5 Ethanol 50 Purified water
- a gel is prepared according to the following formulation (total amount: 100 parts by weight).
- Compound represented by formula (I) Diisopropyl adipate 5 Pyrothiodecane 3 Propylene glycol 10 Macrogol 400 10 Polyoxyethylene (60) hydrogenated castor oil 1 Ethanol 40 Carbopol 940 3 Hydroxypropyl cellulose 1 Diisopropanolamine 1.5 Remaining purified water
- An injection (0.1%) is prepared according to the following formulation.
- An injection (0.1%) is prepared according to the following formulation.
- An injection (0.1%) is prepared according to the following formulation.
- An injection (0.1%) is prepared according to the following formulation.
- the cells were cultured at C for 18 to 20 hours.
- the culture was diluted to about 10 7 ce 11 s / m 1 and used as a cell suspension for inoculation.
- the sample was accurately weighed to about 1 Omg, and dissolved in DMSO (dimethyl sulfoxide) so as to be 1 Omg / ml.
- DMSO dimethyl sulfoxide
- the sample solution was added to a liquid medium (aerobic bacterium; broth for sensitivity measurement, manufactured by Nissi, anaerobic bacterium; GAM bouillon, manufactured by Nissi) to obtain 128 ig / ml. Further, the sample-containing medium solution was serially diluted on a microplate in which 100 ml of the same medium was dispensed (128 to 0.063 ⁇ g / m1).
- Table 2 shows the antibacterial activity against Staphylococcus aureus (IFO 13276), and Tables 3 to 5 show various Gram-positive bacteria [S. epidermidis
- Compound No. 9 is precisely weighed to about 1 Omg, dissolved in DMSO to a concentration of 12.8 mg / ml, and further diluted with DMSO to a multiple of 1: 2 (12.8 to 0.1 m / ml).
- gentamicin sulfate was accurately weighed at about 40 Omg, dissolved in distilled water so as to have a concentration of 409.6 mg / ml, and further diluted with distilled water in several steps to obtain a comparative control drug ( 4 09. 6-0. L mgZml).
- the serially diluted sample solution was added to a liquid medium (Tribute Sauvillon, manufactured by Nissi Corporation) in an amount of 1Z100.
- GM induced a high degree of tolerance.
- Figure 2 shows the test results for the acquisition of resistance to Staphylococcus epidermidis. As a result, compound No. 9 did not induce resistance until the 18th generation. On the other hand, GM induced a high degree of tolerance.
- Slant medium on growth medium test strain One platinum loop (tributyl Tosoh catcher broth, Nissu I Co., Ltd.) was inoculated into 1 0 m l, and 1 8 to 20 hr at 37 e C. was used as a cell suspension for inoculation was diluted to about 1 0 7 cell sZm l cultures.
- Compound No. 9 was accurately measured in an amount of about 1 Omg, and dissolved in DMS0 to be 1 OmgZm1.
- gentamicin sulfate (GM) was accurately weighed at approximately 40 Omg and dissolved in distilled water to obtain 409.6 mg / ml.
- the sample solution was added to a liquid medium (broth for sensitivity measurement, Nissi), and the compound No. 9 was adjusted to 12831111 and the GM was adjusted to 4096 gZm 1. Further, the sample-containing medium was serially diluted on a microplate into which 100 ml of the same medium was dispensed (compound No. 9; 128 to 1 g / m1, GM; 4096 to 1 ⁇ g / m 1) o
- Table 7 shows the antibacterial activity against Escherichia coli (IFO 3972). The results for gentamicin sulfate (GM) as a control drug are also shown.
- test strain One platinum loop on slants growth medium (aerobic bacteria; tributyl Tosoh catcher buoy tio down, two Ssui Co., anaerobes; GAM broth, two Ssui Co.) was inoculated into 10 ml, 37 e C For 18 to 20 hours. Dilute the culture ft to about 10 7 ce 11 s Zm 1 The suspension was used as a cell suspension for inoculation.
- the sample solution was added to a liquid medium (aerobic bacteria; broth for susceptibility measurement, manufactured by Nissi, anaerobic bacteria; GAM broth, manufactured by Nissi) to 128 s / m 1.
- the sample-containing medium solution was further serially diluted (128 to 0.063 / gZml) on a microplate in which the same medium was dispensed in 100 ml portions.
- the cell suspension for inoculation was dispensed in 51 portions into a liquid medium containing a sample, and cultured at 37 for 18 to 20 hours. Then, the growth of the cells was observed.
- the minimum concentration at which the bacteria were observed to be killed was defined as MCC (Minimum Cidal Concentration) and expressed as (1 g / m1).
- Table 8 shows the bactericidal activity against Staphylococcus aureus (IFO 13276), Table 9 shows various gram-positive bacteria [Staphylococcus epidermidis: IFO 1 2993), and propionibacteria (ProDionibacterium acnes: Clinical isolated No. 3)].
- the results for gentamicin sulfate (GM) are also shown as a control drug.
- the 2-aminothiazole derivative has an antibacterial activity or a bactericidal activity against various aerobic and anaerobic gram-positive bacteria and gram-negative bacteria.
- MIC minimum inhibitory concentration
- GM gentamicin sulfate
- these two strains became resistant to gentamicin sulfate (GM), but in the medium containing Compound No. 9, both strains did not cause a large increase in the MIC (minimum inhibitory concentration) due to the passage and became resistant. It was not.
- the antibacterial agent or bactericide of the present invention comprising a 2-aminothiazole derivative and a salt thereof is useful for bacterial infections such as pyoderma, eczema, acne, pressure ulcers, and other diseases. It is expected to be an effective drug against erosion, skin ulcers and secondary infections.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38809/95A AU689972B2 (en) | 1994-11-29 | 1995-11-16 | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
US08/836,924 US5856347A (en) | 1994-11-29 | 1995-11-16 | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
EP95938022A EP0790057B1 (en) | 1994-11-29 | 1995-11-16 | Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof |
DE69526958T DE69526958T2 (de) | 1994-11-29 | 1995-11-16 | Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten |
JP8518570A JP3023178B2 (ja) | 1994-11-29 | 1995-11-16 | 2−アミノチアゾール誘導体およびその塩類からなる抗菌剤または殺菌剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/317737 | 1994-11-29 | ||
JP31773794 | 1994-11-29 | ||
JP6/335388 | 1994-12-22 | ||
JP33538894 | 1994-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996016650A1 true WO1996016650A1 (fr) | 1996-06-06 |
Family
ID=26569125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/002347 WO1996016650A1 (fr) | 1994-11-29 | 1995-11-16 | Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive |
Country Status (8)
Country | Link |
---|---|
US (1) | US5856347A (ja) |
EP (1) | EP0790057B1 (ja) |
KR (1) | KR980700077A (ja) |
AU (1) | AU689972B2 (ja) |
CA (1) | CA2206315A1 (ja) |
DE (1) | DE69526958T2 (ja) |
TW (1) | TW414708B (ja) |
WO (1) | WO1996016650A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0819681A2 (de) * | 1996-07-19 | 1998-01-21 | F. Hoffmann-La Roche Ag | N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung |
WO1999058514A1 (en) * | 1998-05-12 | 1999-11-18 | American Home Products Corporation | (2-acylaminothiazole-4-yl)acetic acid derivatives |
JP2005509675A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | 11−ベータ−ヒドロキシステロイド脱水素酵素タイプ1のインヒビター |
WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
WO2007013572A1 (ja) | 2005-07-29 | 2007-02-01 | Shiseido Company, Ltd. | 毛髪はり・こし改善剤および毛髪用化粧料 |
US7410988B2 (en) | 2004-08-13 | 2008-08-12 | Genentech, Inc. | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
WO2009046784A1 (en) | 2007-10-09 | 2009-04-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
JP2009541367A (ja) * | 2006-06-27 | 2009-11-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシス ピーエルエイ | 2,4,5−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用 |
US7671051B2 (en) | 2001-11-22 | 2010-03-02 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
JP2014526536A (ja) * | 2011-09-23 | 2014-10-06 | バイヤースドルフ・アクチエンゲゼルシヤフト | 芳香族アミドチアゾール、それを含有する化粧用または皮膚科用製剤、ならびに望ましくない皮膚の色素沈着を治療および予防するためのその使用 |
US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
EP3002283A1 (en) | 2003-12-26 | 2016-04-06 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
WO2021097057A1 (en) * | 2019-11-12 | 2021-05-20 | Genzyme Corporation | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity |
CN111166743B (zh) * | 2020-01-02 | 2022-03-22 | 中国医学科学院医药生物技术研究所 | 一类含噻唑结构化合物的抗感染用途 |
JP2023001168A (ja) * | 2017-02-08 | 2023-01-04 | 国立大学法人東海国立大学機構 | 新規な芳香族アミン化合物および蛍光発光材料と紫外線吸収剤 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322137A1 (en) * | 1995-06-22 | 2011-05-18 | Minnesota Mining And Manufacturing Company | Stable hydroalcoholic compositions |
US6623744B2 (en) * | 1995-06-22 | 2003-09-23 | 3M Innovative Properties Company | Stable hydroalcoholic compositions |
FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6582711B1 (en) * | 1997-01-09 | 2003-06-24 | 3M Innovative Properties Company | Hydroalcoholic compositions thickened using polymers |
DE19700795A1 (de) * | 1997-01-13 | 1998-07-16 | Bayer Ag | Verwendung von Aminothiazolen zur Wund- und Hautbehandlung |
AU5871000A (en) * | 1999-06-11 | 2001-01-02 | Paul G. Abrams | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
WO2002062398A2 (en) | 2001-01-08 | 2002-08-15 | Neorx Corporation | Radioactively labelled conjugates of phosphonates |
DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
CN100496493C (zh) * | 2001-08-13 | 2009-06-10 | 詹森药业有限公司 | 2-氨基-4,5-三取代噻唑基衍生物 |
EP1423113A4 (en) * | 2001-08-13 | 2007-04-18 | Phenex Pharmaceuticals Ag | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS |
EP1285914B1 (en) * | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
EP1432706A2 (en) * | 2001-09-26 | 2004-06-30 | Bayer Pharmaceuticals Corporation | 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
AU2007205749B2 (en) * | 2001-11-22 | 2009-04-23 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EA200400708A1 (ru) | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
AU2002364552A1 (en) | 2001-12-13 | 2003-06-30 | Dow Global Technologies Inc. | Treatment of osteomyelitis with radiopharmaceuticals |
PE20030968A1 (es) * | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
CN100357283C (zh) * | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
PL1668105T3 (pl) * | 2003-09-29 | 2019-03-29 | Deb Ip Limited | Kompozycje żelopodobne i pieniące o dużej zawartości alkoholu |
US20050239853A1 (en) * | 2004-02-04 | 2005-10-27 | Tjeerd Barf | New compounds |
DE102004062775A1 (de) | 2004-12-21 | 2006-06-29 | Stockhausen Gmbh | Alkoholischer Pumpschaum |
JP2008531740A (ja) * | 2005-03-07 | 2008-08-14 | デブ ワールドワイド ヘルスケア インコーポレーテッド | シリコーン・ベースの界面活性剤を含むアルコール含有量の高い発泡性組成物 |
UA92746C2 (en) * | 2005-05-09 | 2010-12-10 | Акилайон Фармасьютикалз, Инк. | Thiazole compounds and methods of use |
US7651990B2 (en) * | 2005-06-13 | 2010-01-26 | 3M Innovative Properties Company | Foamable alcohol compositions comprising alcohol and a silicone surfactant, systems and methods of use |
US20070148101A1 (en) * | 2005-12-28 | 2007-06-28 | Marcia Snyder | Foamable alcoholic composition |
CA2636077C (en) * | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 抗c型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
US7994338B2 (en) * | 2006-08-16 | 2011-08-09 | The J. David Gladstone Institutes | Small molecule inhibitors of kynurenine-3-monooxygenase |
EP2054056A4 (en) | 2006-08-16 | 2010-08-25 | J David Gladstone Inst A Testa | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE |
EA200901573A1 (ru) * | 2007-05-22 | 2010-04-30 | Ачиллион Фармасьютикалз, Инк. | Гетероарилзамещенные тиазолы |
MX2009013869A (es) * | 2007-06-21 | 2010-03-17 | Amgen Inc | Proceso para hacer 2-amino-tiazolonas sustituidas. |
CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
WO2010107736A2 (en) * | 2009-03-20 | 2010-09-23 | University Of Virginia Patent Foundation | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials |
DE102010004950A1 (de) * | 2010-01-18 | 2011-07-21 | Remis Gesellschaft für Entwicklung und Vertrieb von technischen Elementen mbH, 50829 | Kühlregal mit Türvorrichtung |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
CA2850022C (en) | 2011-09-27 | 2018-05-01 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
AU2013214846B2 (en) * | 2012-02-01 | 2017-09-07 | City Of Hope | Ribonucleotide reductase inhibitors and methods of use |
CN113968852B (zh) * | 2020-07-23 | 2023-08-15 | 同济大学 | 一种噻唑酰肼类衍生物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673032A (ja) * | 1992-07-07 | 1994-03-15 | Nippon Soda Co Ltd | チアゾール誘導体及びその製法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04173782A (ja) * | 1990-11-08 | 1992-06-22 | Taisho Pharmaceut Co Ltd | 2―スルホンアミド―4,5―ジフェニルチアゾール誘導体 |
DE69132293D1 (de) * | 1991-03-07 | 2000-08-10 | Hisamitsu Pharmaceutical Co | Diphenylthiazolderivate mit antiinflammatorischer aktivität |
JPH0570446A (ja) * | 1991-09-13 | 1993-03-23 | Taisho Pharmaceut Co Ltd | N−チアゾリルスルホンアミド誘導体 |
JPH07149745A (ja) * | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な2−アミノチアゾール誘導体 |
JPH07149746A (ja) * | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な2−置換アミノチアゾール誘導体 |
-
1995
- 1995-11-16 EP EP95938022A patent/EP0790057B1/en not_active Expired - Lifetime
- 1995-11-16 WO PCT/JP1995/002347 patent/WO1996016650A1/ja active IP Right Grant
- 1995-11-16 AU AU38809/95A patent/AU689972B2/en not_active Ceased
- 1995-11-16 US US08/836,924 patent/US5856347A/en not_active Expired - Fee Related
- 1995-11-16 DE DE69526958T patent/DE69526958T2/de not_active Expired - Fee Related
- 1995-11-16 CA CA002206315A patent/CA2206315A1/en not_active Abandoned
- 1995-11-16 KR KR1019970703599A patent/KR980700077A/ko not_active Application Discontinuation
- 1995-12-06 TW TW084112972A patent/TW414708B/zh not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673032A (ja) * | 1992-07-07 | 1994-03-15 | Nippon Soda Co Ltd | チアゾール誘導体及びその製法 |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 86, Abstract No. 115614, (1977). * |
PHARMAZIE, Vol. 45, No. 6, (1990), DAIDONE G. et al., "Salicylanilide and Its Heterocyclic Analogues, A Comparative Study of Their Antimicrobial Activity", p. 441-442. * |
See also references of EP0790057A4 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0819681A2 (de) * | 1996-07-19 | 1998-01-21 | F. Hoffmann-La Roche Ag | N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung |
EP0819681A3 (de) * | 1996-07-19 | 1998-02-04 | F. Hoffmann-La Roche Ag | N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung |
US5958910A (en) * | 1996-07-19 | 1999-09-28 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
KR100247672B1 (ko) * | 1996-07-19 | 2000-04-01 | 프리돌린 클라우스너, 롤란드 비. 보레르 | N-(4-아릴-티아졸-2-일)-설폰아미드 유도체를 함유하는 약제학적 조성물 |
WO1999058514A1 (en) * | 1998-05-12 | 1999-11-18 | American Home Products Corporation | (2-acylaminothiazole-4-yl)acetic acid derivatives |
JP2005509675A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | 11−ベータ−ヒドロキシステロイド脱水素酵素タイプ1のインヒビター |
US7671051B2 (en) | 2001-11-22 | 2010-03-02 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
EP3002283A1 (en) | 2003-12-26 | 2016-04-06 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
US7410988B2 (en) | 2004-08-13 | 2008-08-12 | Genentech, Inc. | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US7795290B2 (en) | 2004-08-13 | 2010-09-14 | Genentech, Inc. | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
WO2007013572A1 (ja) | 2005-07-29 | 2007-02-01 | Shiseido Company, Ltd. | 毛髪はり・こし改善剤および毛髪用化粧料 |
EP2484342A1 (en) | 2005-07-29 | 2012-08-08 | Shiseido Company, Limited | Hair resiliency / body improver and hair cosmetic |
JP2009541367A (ja) * | 2006-06-27 | 2009-11-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシス ピーエルエイ | 2,4,5−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用 |
WO2009046784A1 (en) | 2007-10-09 | 2009-04-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
JP2014526536A (ja) * | 2011-09-23 | 2014-10-06 | バイヤースドルフ・アクチエンゲゼルシヤフト | 芳香族アミドチアゾール、それを含有する化粧用または皮膚科用製剤、ならびに望ましくない皮膚の色素沈着を治療および予防するためのその使用 |
JP2017141242A (ja) * | 2011-09-23 | 2017-08-17 | バイエルスドルフ・アクチエンゲゼルシヤフトBeiersdorf AG | 芳香族アミドチアゾール、それを含有する化粧用または皮膚科用製剤、ならびに望ましくない皮膚の色素沈着を治療および予防するためのその使用 |
JP2023001168A (ja) * | 2017-02-08 | 2023-01-04 | 国立大学法人東海国立大学機構 | 新規な芳香族アミン化合物および蛍光発光材料と紫外線吸収剤 |
WO2021097057A1 (en) * | 2019-11-12 | 2021-05-20 | Genzyme Corporation | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity |
CN115003659A (zh) * | 2019-11-12 | 2022-09-02 | 健赞公司 | 用于治疗由cftr活性缺乏介导的疾患的5元杂芳基氨基磺酰胺 |
CN111166743B (zh) * | 2020-01-02 | 2022-03-22 | 中国医学科学院医药生物技术研究所 | 一类含噻唑结构化合物的抗感染用途 |
Also Published As
Publication number | Publication date |
---|---|
AU689972B2 (en) | 1998-04-09 |
DE69526958T2 (de) | 2003-01-16 |
AU3880995A (en) | 1996-06-19 |
CA2206315A1 (en) | 1996-06-06 |
EP0790057A1 (en) | 1997-08-20 |
EP0790057A4 (en) | 1998-10-21 |
DE69526958D1 (de) | 2002-07-11 |
US5856347A (en) | 1999-01-05 |
TW414708B (en) | 2000-12-11 |
KR980700077A (ko) | 1998-03-30 |
EP0790057B1 (en) | 2002-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996016650A1 (fr) | Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive | |
TWI362261B (en) | Pharmaceutical composition for treatment of an infection in animals | |
JP4657603B2 (ja) | 持続放出性の生体粘着性治療システム | |
JP2834951B2 (ja) | 細菌性腟症用予防および治療剤 | |
US6492395B1 (en) | Topical formulation of alkyl-, phenyl-pyridone | |
KR20080046673A (ko) | 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제 | |
CN1976723B (zh) | 制备治疗或预防感染性疾病的药物的用途 | |
RO109156B1 (ro) | Compozitie cu metronidazol,pentru infectiile vaginale si metoda de tratament cu aceasta | |
JP2020505469A (ja) | 治療用アプレミラスト局所組成物 | |
JPH09165344A (ja) | 膣用固形医薬品組成物 | |
JP2007077152A (ja) | 膣のpHを低下させるための組成物および方法 | |
EP2094358B1 (en) | Imidazoles for treating multi-drug resistant bacterial infections | |
CN101594869B (zh) | 可用于治疗感染性疾病的噻吨衍生物 | |
WO2013047530A1 (ja) | 抗真菌剤 | |
JP3023178B2 (ja) | 2−アミノチアゾール誘導体およびその塩類からなる抗菌剤または殺菌剤 | |
US20130089577A1 (en) | Novel ester containing compositions and methods | |
WO1991003244A1 (en) | Composition for percutaneous administration | |
WO2001003742A1 (fr) | Composition de medicament pour administration topique | |
AU2003206120B2 (en) | Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives | |
US20050158371A1 (en) | Novel external agent | |
JPWO2018124281A1 (ja) | 外用組成物 | |
JP2008513450A (ja) | 粘膜又は皮膚医療又は衛生処理システム | |
JP2001163783A (ja) | 皮膚疾患治療用外用剤 | |
JPH1121239A (ja) | ナフト[2,3−d]チアゾール−4,9−ジオン誘導体からなるヒト又は動物用抗菌又は殺菌剤 | |
WO2006099196A1 (en) | Novel method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08836924 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2206315 Country of ref document: CA Ref country code: CA Ref document number: 2206315 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970703599 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995938022 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995938022 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970703599 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970703599 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995938022 Country of ref document: EP |